INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
30.03.26 | 15:25
0,930 Euro
-2,62 % -0,025
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,090 | 1,130 | 30.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Innate Pharma Q4 2025: Strategischer Fokus und Kostendisziplin prägen Earnings Call | 4 | Investing.com Deutsch | ||
| Do | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| Do | Innate Pharma GAAP EPS of -€0.55, revenue of €9.01M | 1 | Seeking Alpha | ||
| Do | Innate Pharma SA: Innate Pharma Reports Full Year 2025 Financial Results and Business Update | 765 | Business Wire | Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation... ► Artikel lesen | |
| 19.03. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.03. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results | 290 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2... ► Artikel lesen | |
| 11.03. | Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline | 2 | Investing.com | ||
| 19.02. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026 | 338 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 18.02. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 18.02. | Innate Pharma SA: Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference | 326 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced... ► Artikel lesen | |
| 07.01. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.01. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025 | 482 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 22.12.25 | Innate Pharma SA - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.12.25 | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 | 417 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 11.12.25 | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.12.25 | Innate Pharma SA: Innate Pharma Releases Its 2026 Financial Calendar | 680 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2026 financial calendar:
March 26, 2026: Publication of 2025 financial... ► Artikel lesen | |
| 28.11.25 | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 28.11.25 | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 | 622 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 17.11.25 | Innate Pharma SA: Innate Pharma to Present at Jefferies Global Healthcare Conference | 412 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of... ► Artikel lesen | |
| 13.11.25 | Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances | 1 | Investing.com |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVORYON THERAPEUTICS | 1,332 | -1,04 % | Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology | Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Halle (Saale) / Munich, Germany... ► Artikel lesen | |
| XOMA ROYALTY | 25,600 | -0,78 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| TME PHARMA | 0,074 | 0,00 % | TME Pharma NV: TME Pharma extends financial runway to over 12 months | TME Pharma extends financial runway to over 12 months Berlin, Germany, March 9, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| CANSINO BIOLOGICS | 3,564 | -1,06 % | CanSino Biologics Inc: CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader | HONG KONG, Mar 31, 2026 - (ACN Newswire) - HONG KONG, Mar 31, 2026 - (ACN Newswire) - China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry,... ► Artikel lesen | |
| KARYOPHARM | 4,660 | +0,43 % | Karyopharm Therapeutics Inc.: Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction | - While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS -
- SENTRY... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,288 | +3,23 % | MEREO BIOPHARMA GROUP PLC ADR - Ruhe als strategische Zone | ||
| KALVISTA PHARMACEUTICALS | 16,200 | +1,25 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference | Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability KalVista Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen | |
| ADICET BIO | 5,550 | +2,78 % | XFRA 1IJ: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ANNOVIS BIO | 1,774 | +2,31 % | Annovis Bio: Finanzvorstand geht, CEO übernimmt kommissarisch | ||
| INTEGRA LIFESCIENCES | 8,000 | +0,63 % | Integra LifeSciences Holdings Corporation: Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance | PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31... ► Artikel lesen | |
| RHYTHM PHARMACEUTICALS | 72,50 | +7,41 % | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or ... | -- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 3,940 | -2,96 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| RECCE PHARMACEUTICALS | 0,296 | +15,62 % | Recce Pharmaceuticals Secures Brazilian Patent for Anti-Infectives | ||
| PRAXIS PRECISION MEDICINES | 276,44 | -4,53 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | ||
| QIAGEN | 34,540 | +1,75 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen |
INNATE PHARMA SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,62 % bei einem Aktienkurs von 0,930 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.